EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Genolution Inc. (225220) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Genolution Inc. KRW 437, price KRW 1,469, upside -70.2%, quality 42 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · KR · ISIN KR7225220003

GI Thin data Oct 3, 2026

Genolution Inc.

225220 · KQ

Weakest SetupStrongly overvalued and low quality.

Low debt
Quality 42/100
Fair value 437.18 KRW · Strongly overvalued (−70.2%)
Weak Growth (revenue 5y −35.7 %/yr in KRW)
Loss-making · -46.5% net margin (TTM)
Negative free cash flow
Trails peers (3/8)
Narrow moat 10/100
Thin data
Watch Genolution Inc. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

9,205 KRW 1,030 KRW Fair Value 437.18 KRW May 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.

How to read this chart

60‑month range 1,030 KRW – 9,205 KRW · fair‑value band 288.54 KRW – 546.48 KRW · the 1,469 KRW price screens above the 437.18 KRW fair value. Dashed = 300-day average. As of Oct 3, 2026.

Follow Genolution in your weekly email

Every Wednesday you see whether Genolution is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Genolution Inc. manufactures and sells IVD medical instruments in South Korea and internationally. Its products are primarily focused on molecular diagnostics, ribonucleic acid interference (RNAi) services, and double-stranded RNA (dsRNA) synthesis technology.

Show more

Genolution Inc. manufactures and sells IVD medical instruments in South Korea and internationally. Its products are primarily focused on molecular diagnostics, ribonucleic acid interference (RNAi) services, and double-stranded RNA (dsRNA) synthesis technology. The company offers Nextractor NX-Duo, Nextractor NX-32N/45N, Nextractor NX-Jr, Nextractor NX-24SA, NGS library preparation equipment, DNA/RNA extraction kits. It also develops and manufactures instruments and reagents for DNA/RNA; provides long dsRNA synthesis services; and siRNA/miRNA/shRNA synthesis service and related products. Genolution Inc. was founded in 2006 and is based in Seoul, South Korea.

Stock analysis

Genolution Inc. (225220) currently trades at 1,469 KRW, while our model-based Fair Value estimate is 437.18 KRW, 70.2% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 94/100, which puts the evidence level at low.

Scenario range: 288.54 KRW (bear) to 546.48 KRW (bull), the price of 1,469 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Genolution Inc. reported revenue of 9.4B KRW in FY2025 versus 72.8B KRW in FY2021, a compound −40.1%/yr. Reported net income was −11.6B KRW in FY2025.

Key figures

Market cap 26.5B KRW (≈ $19.7M) · P/S ratio 2.65 · Net margin −124% · Return on equity −7.9% · Return on assets (EBIT) 6.3% · Operating margin −51.6% · Revenue (TTM) 10.0B KRW · Revenue growth (YoY) +7.3%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).

What moves the price

The share trades about 37% below its 52-week high and 43% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −70%, 225220 screens richer than that median.

Fair Value models

Bear 288.54 KRW Fair Value 437.18 KRW Bull 546.48 KRW
Price 1,469 KRW · Upside -70.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) 1,892 KRW 2,535 KRW 3,784 KRW 54
All 1 models by family
Asset-Based
NCAV (Graham) 1,892 KRW 2,535 KRW 3,784 KRW 54

Open the full fair value analysis →

Notify me when 225220 reaches fair value

Put 225220 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 42/100

Of which business quality 42 · Market factors (momentum, volatility) 42

Profitability 1
Margins and returns on capital today
Quality Growth 52
Are margins and returns improving?
Cashflow 2
Earnings quality: real cash, not paper profit
Fin. Strength 60
Balance sheet, leverage, solvency risk
Investment 95
Disciplined investing over empire-building
Low Volatility 76
Calm price path (market factor)
Momentum 35
Price trend over the last 3–12 months (market factor)
52W Momentum 15
Distance to the 52-week high (market factor)
Net Issuance 81
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 6/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+31.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−37.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−35.7%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
63.4% (2020) → −91.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

225220 screens overvalued: fair value 70% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Genolution Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 609 stocks

Beats the industry median on 2/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 42 · Below median
Fair Value upside −70.2% · Below median
Profitability
Return on assets −4.8% · Above median
Net margin (TTM) −46.5% · Bottom 25%
Operating margin (TTM) −51.6% · Bottom 25%
Growth and dividend
Revenue growth 7.3% · Above median
Balance sheet
Debt / equity 0.28× · Highest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)37 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)86 · sector 97
DIVIDEND (yield)0 · sector 22

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $504.73 $555.20 +10%
Regeneron Pharmaceuticals, Inc REGN $735.20 $1,275 +73%
argenx SE ARGX $959.49 $918.60 −4%
CSL Limited CSL A$175.35 A$192.89 +10%
Samsung Biologics Co 207940 1,354,000 KRW 1,489,400 KRW +10%
BeOne Medicines AG ONC $360.85 $280.94 −22%
Alnylam Pharmaceuticals, Inc ALNY $255.96 $217.88 −15%
Royalty Pharma plc RPRX $58.21 $19.01 −67%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
WuXi Biologics (Cayman) Inc 2269 HK$53.00 HK$58.30 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Genolution Inc. · Fair Value
437.18 KRW −70%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Genolution Inc. Fair Value". https://www.fairvalue-calculator.com/stock/225220

Frequently asked questions

Is Genolution Inc. (225220) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of 437.18 KRW versus a price of 1,469 KRW, about −70% upside (overvalued).
What is the fair value of 225220?
Our model-based fair value for Genolution Inc. is 437.18 KRW (as of Oct 3, 2026), built from audited fundamentals. The current price: 1,469 KRW.
What is the quality score of 225220?
Genolution Inc. has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Genolution Inc. (225220)?
Our model-based price target is the fair value of 437.18 KRW (as of Oct 3, 2026) from 1 valuation models. Cautious scenario 288.54 KRW, optimistic scenario 546.48 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Genolution Inc. stock forecast for 2026?
Our models put fair value at 437.18 KRW, about −70% upside versus a price of 1,469 KRW (overvalued). Cautious scenario 288.54 KRW, optimistic scenario 546.48 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Genolution Inc. (225220)?
Genolution Inc. reported trailing-twelve-month revenue of about 10.0B KRW (latest available figure, as of Oct 3, 2026).
What is the intrinsic value of Genolution Inc. (225220)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Genolution Inc. it is 437.18 KRW per share (as of Oct 3, 2026), against a price of 1,469 KRW. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Genolution Inc. stock overvalued or undervalued in 2026?
As of Oct 3, 2026, 225220 trades above its calculated fair value: price 1,469 KRW, fair value 437.18 KRW, a gap of about −70% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 225220?
No. The price is what the market pays today (1,469 KRW); the fair value is what the company's own numbers justify (437.18 KRW). For Genolution Inc. the two are 1,032 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Genolution Inc. worth?
The market values Genolution Inc. at about 26.5B KRW (market capitalisation, as of Oct 3, 2026). Per share that is 1,469 KRW; our models calculate a fair value of 437.18 KRW per share.
What do the bullish and bearish scenarios say about 225220?
Our models span a range for Genolution Inc.: cautious scenario 288.54 KRW, base 437.18 KRW, optimistic 546.48 KRW per share (as of Oct 3, 2026, price 1,469 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Genolution Inc. (225220)?
Balance-sheet figures for Genolution Inc. (as of Oct 3, 2026): return on equity −7.9%, debt of 0.28 per unit of equity. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is 225220 from its 52-week high?
Genolution Inc. trades at 1,469 KRW, about 37% below its 52-week high of 2,315 KRW and 43% above the low of 1,030 KRW (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of 437.18 KRW is for.
Which stocks are comparable to Genolution Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Genolution Inc. stock attractive at the current price?
The data as of Oct 3, 2026: price 1,469 KRW, calculated fair value 437.18 KRW (−70%), Quality Score 42/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 225220 calculated?
We run Genolution Inc. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 437.18 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1 % above its aggregate fair value. Genolution Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Genolution Inc. (225220)?
The closing price on Oct 2, 2026 was 1,469 KRW. Our model-based fair value is 437.18 KRW, about −70% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Genolution Inc. right now?
The price sits above even our optimistic bull case (546.48 KRW). The favourable scenario is already priced in. Weak quality (42/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (288.54 KRW to 546.48 KRW) leaves room in how you read the outcome.

Key figures of Genolution Inc.

How large is the market capitalisation of Genolution Inc. (225220)?
The market capitalisation of Genolution Inc. is 26.5B KRW (≈ $19.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Genolution Inc. (225220)?
The price-to-sales ratio of Genolution Inc. is 2.65 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Genolution Inc. (225220)?
The net margin of Genolution Inc. is −124% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Genolution Inc. (225220)?
The return on equity (ROE) of Genolution Inc. is −7.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Genolution Inc. (225220)?
On an EBIT basis the return on assets of Genolution Inc. is 6.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Genolution Inc. (225220)?
The operating margin of Genolution Inc. is −51.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Genolution Inc. (225220)?
Revenue at Genolution Inc. is growing +7.3% versus a year earlier (3y avg −37.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Genolution Inc. (225220) generate?
The free cash flow of Genolution Inc. is −7.5B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Genolution Inc. (225220) carry?
The net debt of Genolution Inc. is 5.1B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Genolution Inc. in the live analysis

One click puts Genolution Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.